Bio-Rad posts robust margins and liquidity, while Charles River leads in global drug discovery services. Explore how their ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BIO boosts ddPCR growth with the Stilla acquisition, QX700 launch and expanded assays for molecular testing. Bio-Rad's clinical diagnostics sees strong demand, led by IH-500 NEXT and growth in ...

With a market cap of $9.5 billion, Bio-Rad Laboratories, Inc. (BIO) operates in the healthcare and life sciences industry. The Hercules, California-based company develops and manufactures a wide range ...

(1) Excluded items identified in the reconciliation schedule are tax effected by application of a non-GAAP effective tax rate. The non-GAAP tax provision is adjusted for items, the nature of which and ...

BIO unveils four new ddPCR systems, enhancing its Life Science offerings post-Stilla Technologies acquisition. BIO's new systems improve workflow, precision and throughput across PCR applications in ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based ...

Bio-Rad Laboratories Inc (NYSE:BIO) shares are trading lower after the company lowered its annual revenue growth forecast, citing the uncertain pace of the biopharma sector's recovery and the ongoing ...

Rad's EZ-Check Listeria spp. and EZ-Check Listeria monocytogenes Kits for the detection of Listeria spp. and Listeria monocytogenes in food products and environmental samples.

Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, courtesy of its strong traction in the QX600 Droplet Digital PCR (ddPCR) platform. Demand for its quality control and ...